The KEYNOTE-024 trial was designed to evaluate the efficacy of pembrolizumab monotherapy against platinum-based chemotherapy in NSCLC patients whose tumors expressed PD-L1 at levels of 50% or greater and who did not harbor the driver mutations. Here, CD274 is linked to non-small cell lung carcinoma.